ARCHIVES

Vectibix Non-Inferior to Erbitux In Wild-Type Metastatic Disease

This article is from The Cancer Letter archive.

Vol. 36 No. 10 | October 25, 2013

Download PDF Visit The Full Archive

Related Articles

LDK378 Demonstrates 58 Percent Overall Response Rate in Phase I

April 25, 2014

Techniclone Wins Patent For Tumor Necrosis Therapy.

February 25, 2000

NCI Predicts 42 Percent Increase In Number of Senior Survivors

October 28, 2011

Ten Is The New 12: Medicare Lowers Hemoglobin Targets For ESA Use.

August 3, 2007

Advisors Approve NCI Plan To Contract For Early Clinical Trials Of Imaging Agents.

March 31, 2000

RFAs For New Improve Accrual Of Minorities, Women

February 2, 1996